DiversifyRx

JANUARY 30, 2025

Pharmacy cash revenue is a must-have for pharmacy owners. Cash-based revenue is no longer just a buzzword; its a necessity for independent pharmacies looking to thrive in todays challenging healthcare landscape. Relying solely on PBM reimbursements has become a losing game for many. By incorporating cash-based services and products, pharmacy owners regain control of their profitability while delivering immense value to their communities.

Independent Pharmacies

Drug Topics

JANUARY 30, 2025

A survey conducted by 3 Axis Advisors revealed potential impacts of the Inflation Reduction Acts Medicare Drug Price Negotiation Program.

Community Pharmacies

Pharmacy Times

JANUARY 30, 2025

The drug is a selective NaV1.8 pain signal inhibitor and is the first new class of medication to treat acute pain in over 20 years.

FDA

Drug Topics

JANUARY 30, 2025

Adolescent obesity rates have risen in recent years, and a number of treatment options can be taken to help reduce the risk of a variety of associated medical problems.

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

JANUARY 30, 2025

Digoxen is the active ingredient found in the foxglove plant and is commonly used to treat heart failure.

Drug Topics

JANUARY 30, 2025

The decision makes the selective NaV1.8 pain signal inhibitor the first new class of medicine to treat acute pain in over 20 years.

FDA

Drug Topics

JANUARY 30, 2025

Joseph DiPiro, PharmD, FCCP, FAAAS, broke down the importance of the ASHP Pharmacy Forecast and the process in which its content is curated.

PharmaVoice

JANUARY 30, 2025

“Are you supportive of these onesies?” Sen. Bernie Sanders asked Kennedy, pointing to infant clothing stamped with anti-vaccine slogans — and more from yesterday’s confirmation hearing.

Vaccines

Drug Topics

JANUARY 30, 2025

Patients with diabetes and prediabetes have older brain ages than their chronological age compared with normoglycemic patients.

Pharmacy Times

JANUARY 30, 2025

Meloxicam and rizatriptan reduces migraine pain and help patients return to normal functioning with efficacy through 24 to 48 hours after a single dose for some patients.

FDA

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Drug Topics

JANUARY 30, 2025

In a post hoc secondary analysis of the BP-CATCH trial, researchers explored the best ways of screening children with high blood pressure and managing their care.

Pharmacy Times

JANUARY 30, 2025

Leukemia biology may predict patterns of blinatumomab failure after initial response.

Fierce Healthcare

JANUARY 30, 2025

Pharmacy benefit management giant Express Scripts unveiled several steps it's taking to boost transparency and mitigate high costs members may face. | Pharmacy benefit management giant Express Scripts unveiled several steps it's taking to boost transparency and mitigate high costs members may face.

Pharmacy Times

JANUARY 30, 2025

The overall survival data were immature at the primary analysis of the study.

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Healthcare

JANUARY 30, 2025

The agency said it is "considering opportunities to bring greater transparency" and will consider stakeholder feedback on the program. In response, Senate Democrats pushed HHS secretary nominee Robert F. Kennedy Jr. for reassurances that the program is safe from drugmakers' lobbying.

Pharmacy Times

JANUARY 30, 2025

Pharmacists can improve hyperkalemia management through collaboration and innovation.

Fierce Healthcare

JANUARY 30, 2025

The Cigna Group reported $1.4 billion in profit for the fourth quarter of 2024, falling short of Wall Street's expectations as it was dinged by elevated medical costs that continue to plague the industry.

Pharmacy Times

JANUARY 30, 2025

Lu-edotreotide (ITM-11; ITM) met its primary endpoint of prolonging progression-free survival (PFS).

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

JANUARY 30, 2025

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning, today we look at RFK Jr.’s first day of confirmation hearings and the latest biotech news.

Pharmacy Times

JANUARY 30, 2025

The court also addressed the employers basis for ordering a drug test.

pharmaphorum

JANUARY 30, 2025

Stay ahead of the curve by exploring the key trends shaping pharmaceutical operations in 2025, including cybersecurity, efficiency, workforce management, and technology advancements. Learn more about these important industry developments.

Pharmacy Times

JANUARY 30, 2025

Hypertrophic cardiomyopathy is caused by abnormal genes in the heart muscle, causing the left ventricle to become thicker and effecting blood flow.

pharmaphorum

JANUARY 30, 2025

UK Biobank study suggests someone's risk of premature ageing or cognitive decline could be predicted using a simple ECG reading supported by an AI

Pharmacy Times

JANUARY 30, 2025

Diagnosing anemia, a serious and common complication of patients with myelofibrosis, could be made easier with the use of red cell distribution width assessment.

STAT

JANUARY 30, 2025

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds.  Sign up here. Good morning! It’s Thursday. Friday eve. Can you believe it?

Pharmacy Times

JANUARY 30, 2025

Additionally, the authors observe that childhood-onset epilepsy is associated with an earlier age at the onset of amyloidosis.

Fierce Healthcare

JANUARY 30, 2025

Follow along today for ongoing coverage of Robert F. Kennedy Jr.'s second Senate confirmation hearing. | Follow along today for ongoing coverage of Robert F Kennedy Jr.'s second Senate confirmation hearing.

Pharmacy Times

JANUARY 30, 2025

Melody Chang, RPh, MBA, BCOP, explains how American Oncology Network leveraged its experience with the Oncology Care Model to address challenges when adopting the Enhanced Oncology Model.

pharmaphorum

JANUARY 30, 2025

ALK-Abello's Acarizax for dust mite allergy should soon be available through the NHS in England, Wales, and Northern Ireland, but not in Scotland.

Pharmacy Times

JANUARY 30, 2025

Apitegromab is a muscle-targeted therapy for improvement of motor function in individuals with spinal muscular atrophy.

FDA

pharmaphorum

JANUARY 30, 2025

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker.

Pharmacy Times

JANUARY 30, 2025

The supplemental new drug application is based on objective response rate and duration of response results from a phase 2 study that assessed the efficacy and safety of belzutifan.

FDA

Pharmaceutical Technology

JANUARY 30, 2025

The pathway allows medicine developers to work with the regulators, the NHS and health technology assessment bodies.